Haing medicine " wrong path " : Go up repeatedly black a list of names posted up is call-overed by

Whose fault?

On May 14, wholy-owned subsidiary breaths out haing drug stock the yew alcohol that medical live thing produces injects fluid, examine via inspection agency discover disagreement compasses, meet with bureau of national medicine inspect " call-over " . Before this, breath out the medicines and chemical reagents with medical subordinate stock to already went up for many times quality " black a list of names posted up " . Meanwhile, outstanding achievement of haing drug stock also appeared to glide continuously the predicament to deficit, after twice defer reply hands in place to ask ask, on May 15, even share just gives in exam paper.

Exposure reported first quarter 2019, data shows, haing drug stock realizes battalion to receive 2.674 billion yuan first quarter, relatively on year the corresponding period glides 6.43% ; Vest in appears on the market the net profit loss of company shareholder 145 million yuan, and go up gain of year of criterion of the corresponding period 140 million yuan.

Reply announcement is mentioned, haing drug stock bright the reason that in recent years medical industry income glides considerably includes impact of environmental protection policy, invite public bidding to depreciate influence, cure changes ageing of structure of policy impact, product and in-house element; Commercial board piece the reason that income glides includes trade policy impact, company to be opposite actively sale of control of partial medical establishment.

Public data shows, haing drug stock is look forward to of medicine of domestic old brand, accuse a partner to be haing drug group. The company is had " haing medicine " , " 3 essence " , " world " , " the lid in the lid " , " protect red " 5 well-known logo and " world " the access of old name of a China. In antibiotic, blame prescription drug and health care are tasted wait for a domain to all have extensive position. But in recent years, its are faced with product line ageing, battalion to control next demote problems.

Recently, bureau of national medicine inspect issues the give public notice that does not accord with a regulation about 23 batch medicines and chemical reagents, announce shows, this medicines and chemical reagents examines the 23 batch drug that discovers 8 enterprises are produced does not accord with a regulation, do not accord with formulary project to include to see eyewinker, granuality, catalpa alcohol, character wait, and involve much home to produce a business.

Among them, limited company of engineering of living things of haing drug group (next weighing that breath out medical live thing) fluid of yew alcohol inject (manufacturing lot number: 201709012) , academy of calibrating of medicines and chemical reagents of classics China food examines, discovery " visible eyewinker " the project does not accord with a regulation.

Bureau of national medicine inspect expresses, to according with formulary medicines and chemical reagents, supervisory management department of relevant medicines and chemical reagents already asked relevant enterprise suspends a sale using, recall, begin do not accord with formulary reason to investigate, undertake rectifying and reform. In the meantime, supervisory management department of provincial medicines and chemical reagents is right related requirement of bureau of national medicine inspect relevant enterprise and unit basis " Pharmaceutical Affairs Law of People's Republic of China " the illegal behavior of medicines and chemical reagents of false bad of carry out of formulary opposite produce and sale undertakes put on record is investigated.

The data shows, haing drug live thing held water 1995, the yew alcohol that haing drug live thing produces injects fluid (much general is comfortable) to change medical tumour kind product, main component is yew alcohol, ovarian cancer and breast cancer and blame cellule lung cancer (a gleam of of NSCLC) and second line cure, and neck cancer, esophagus cancer, tumour of sperm former cell, recrudesce is not He Jinshi lymphatic tumour.

In fact, breath out medical group to had become qualitative check black a list of names posted up " familiar face " . 2018 the beginning of the year, the news that according to Heilongjiang bureau of the inspect that feed medicine announces shows, lot number of sale of branch of medicinal material of limited company of medicine of haing drug group is in for the alum of 151101 [examination] below " ammonium salt " do not accord with relevant provision.

Public data shows, in July 2017, designation is world of haing drug group a Chinese traditional medicine the alum that finite liability company produces prepared herbal medicine in small pieces ready of decoction, be exposed to the sun because of ammonium salt issue unqualified.

In November 2016, branch of haing drug group breaths out medicine 6 factories because partial product of production does not accord with food safety standard to be fed by Heilongjiang punishment of medical inspect bureau.

In December 2014,

Guo Fan Li expresses essayist of finance and economics publicly, drug production company appears again and again quality problem basically is superintending systematic disorder at quality, the company is right quality problem ignored. Haing drug group produces market effect with strong advertisement offensive, make company name quickness expand, swift and violent violent wind promotes outstanding achievement, pledge to medicines and chemical reagents the quantity did not take seriously particularly. Because technology of partial drug production is opposite simple, the enterprise may relax a requirement to reduce manufacturing cost, and the country is insufficient to the superintendency strength of the state-owend enterprise, bring about drug problem frequency to go out.

However, haing medicine needs to solve problem of quality of medicines and chemical reagents urgently not only, still answer as soon as possible fill deficit crosses 100 million yuan large deficit.

Annals showed medical share 2018, realize battalion to receive ten billion eight hundred and forteen million yuan in those days, decrease compared to the same period 10.02% ; Net profit 346 million yuan, decrease compared to the same period 14.95% . Its are clean first quarter this year profit is deficit more 145 million yuan, and predict half year reported net profit still is 2019 lose.

On April 23, haing drug stock gets Shanghai stock exchange " about be opposite year report reached Inc. of haing drug group 2018 the examine and verify of after the event that reports first quarter asked ask case 2019 " . Case asking ask asks to breath out medical stock at replying before April 30, 2019, press a requirement to edit accordingly and be announced to reporting regularly at the same time.

However, haing drug stock was mixed on April 30 released delay reply to ask ask case announcement respectively on May 11, as a result of,say this second " case asking ask " involve content more, and need year of careful accountant to express an opinion, because this company predicts,cannot be inside formulary time finish " case asking ask " the reply works.

Haing drug stock says, company business income glides for years continuously, vest in appears on the market the net gain of company shareholder glides 2 years continuously, 2019 vest in appears on the market first quarter the net profit of company shareholder turns deficient, predict half year reported net profit still is 2019 negative.

Example of business of an ancient name for China consults calendar year money signs up for discovery, battalion of haing drug stock closes to already glided 5 years continuously, from 2013 battalion receives eighteen billion and ninety-two million yuan to glide to battalion received ten billion eight hundred and forteen million yuan 2018, 5 years reduce nearly 8 billion yuan. And the net gain of haing drug stock also glides two years continuously, nowadays, outstanding achievement was immersed in on deficit 100 million yuan again first quarter 2019 " lair " .

Look from fractionize trade situation, industry of medicine of haing drug stock, commerce board piece business income all presents next slippery trends 4 years recently, accumulative total falls it is respectively 38.16% with 27.36% . Look from product structure, its are fought affect kind of product to serve as one of main products, business income scale glides from 2.937 billion yuan of 2015 reach 1.241 billion yuan of 2018, accumulative total falls 57.75% , at the same time gross profit is led 29.69% , relatively glided 2016 5.19 percent.

Medical treatment strategy seeks advice from Zhao Heng of author of company Latitude Health to express, haing drug group is faced with ageing of administrative occurrence flaw, product to wait for a problem at present, the company needs to through rectifying and reform ability in the round the opportunity promotes outstanding achievement afresh.

([example of business of an ancient name for China] fasten autograph of today's top headlines to make an appointment with an author, rank finance and economics of today's top headlines 3 years continuously from odd front row of media year a list of names posted up.